Icosavax

Icosavax announced Wednesday the close of $100 million in Series B financing.

The funds will support the development of the biotech’s bivalent RSV and human metapneumovirus vaccine through initial clinical studies, continued evaluation of its virus-like particle (VLP) Covid-19 vaccine candidate, and expansion of its pipeline of other VLP vaccine candidates targeting respiratory diseases, the press release said.

The state of the hunt:

CEPI expanded its funding for Clover Biopharmaceuticals’ S-Trimer Covid-19 vaccine candidate to $328 million.
  Humanigen touted positive interim Phase 3 results for lenzilumab and announced a cooperative R&D deal with the U.S. government.
  Russia approved a domestic version of Fujifilm’s Avigan for coronavirus outpatients, dubbing the product “the first [f]avipiravir-based drug in the world approved for the treatment of COVID-19.”